Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

February 4, 2021 4:02 PM EST
Get Alerts FLDM Hot Sheet
Price: $4.61 --0%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company’s management will participate in investor meetings at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021.

Chris Linthwaite, President and CEO, will participate in a virtual fireside chat and present updates regarding Fluidigm’s business strategy and financial performance at 2:00 pm ET. A live webcast and subsequent replay will be available in the Events & Presentations section of the Fluidigm investor website. The replay will be available two hours after the live session and will be archived for the following 90 days.

About FluidigmFluidigm (Nasdaq: FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.

Fluidigm, the Fluidigm logo, Advanta and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is for In Vitro Diagnostic Use. It is for Use under Emergency Use Authorization Only. Rx Only. Other Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Available Information We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.

Contact:

Agnes LeeVice President, Investor RelationsFluidigm Corporation650 416 7423agnes.lee@fluidigm.com

Primary Logo

Source: Fluidigm Corporation


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Globe Newswire, Press Releases

Related Entities

Twitter, BTIG